The rise of Viagra and its effect on the pharmaceutical landscape presents a intricate question for investors. While the early sales statistics were impressive, the intellectual property has expired, leading to a flood of copycat alternatives that are chipping away at earnings. Furthermore, the sector is facing issues related to demographic tren… Read More